Katsuya Higo
About
In The Last Decade
Katsuya Higo
27 papers receiving 370 citations
Peers
Comparison fields: 5 of 70
- Molecular Biology 190
- Physiology 126
- Epidemiology 85
- Endocrinology, Diabetes and Metabolism 73
- Cardiology and Cardiovascular Medicine 60
Countries citing papers authored by Katsuya Higo
This map shows the geographic impact of Katsuya Higo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katsuya Higo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katsuya Higo more than expected).
Fields of papers citing papers by Katsuya Higo
This network shows the impact of papers produced by Katsuya Higo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katsuya Higo. The network helps show where Katsuya Higo may publish in the future.
Co-authorship network of co-authors of Katsuya Higo
This figure shows the co-authorship network connecting the top 25 collaborators of Katsuya Higo. A scholar is included among the top collaborators of Katsuya Higo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katsuya Higo. Katsuya Higo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 4 | |
| 2 | 1 | |
| 3 | 7 | |
| 4 | 22 | |
| 5 | 23 | |
| 6 | 7 | |
| 7 | 39 | |
| 8 | 4 | |
| 9 | 1 | |
| 10 | 7 | |
| 11 | 3 | |
| 12 | 13 | |
| 13 | 3 | |
| 14 | 39 | |
| 15 | 3 | |
| 16 | 4 | |
| 17 | 9 | |
| 18 | Antiplatelet effects of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e] oxepine-2-carboxylate monohydrate. | 9 |
| 19 | Actions of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)-ethylidene]-6,11- dihydrodibenz[b,e]oxepine-1-carboxylate monohydrate on smooth muscle preparations. | 8 |
| 20 | 6 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.